Islet Sciences, Inc. (ISLT) Announces Receipt of Japanese Patent Covering New Diabetes Medications
Biotechnology company Islet Sciences has announced the receipt of a Japanese patent for allowed claims covering new medications for diabetes. The notice of allowed claims for Patent Application No. 2008-529208 includes the use and composition for small molecules in preventing or treating pathological inflammatory or autoimmune condition – in particular, type 1 diabetes, atherosclerosis, type 2 diabetes, disorders related to visceral obesity, multiple sclerosis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, and Alzheimer’s disease. The patent signifies an additional aspect to the value of Islet Sciences’ therapies, which represent a large market opportunity for the diabetic community and also for the…